FMDV Virus-Like Particle Production Yield and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for foot-and-mouth disease (FMD) are limited by the need for high containment facilities, fragility of inactivated virus structures, and low yield and thermostability of virus-like particles (VLPs) produced in baculovirus expression systems, leading to a global undersupply and stability issues, especially for certain serotypes.
Innovation Solution
A method involving the baculovirus expression system to produce FMDV VLPs by infecting insect cells with a baculovirus expression vector, culturing them for at least 5 days to allow VLPs to mature and be transported to the extracellular medium, where they are more stable and can be harvested, increasing yield and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inactivated FMD virus is used for vaccine production, then immunogenicity is achieved, but product stability deteriorates due to fragility at acidic pH and elevated temperatures
Solution Approach 1:
The patent produces virus-like particles (VLPs) that replicate the structural and immunogenic properties of intact FMDV capsids without containing actual viral genetic material. These VLPs are self-assembled from recombinant capsid proteins (VP1, VP2, VP3, VP4) expressed in insect cells, creating a stable copy that maintains immunogenicity while eliminating the fragility and safety concerns of inactivated whole viruses
Solution Approach 2:
The patent modifies the physical and chemical parameters of the vaccine product by using VLPs instead of inactivated viruses. VLPs exhibit enhanced stability parameters including resistance to acidic pH, thermal stability at elevated temperatures, and improved shelf-life, while maintaining the critical immunogenic parameter through proper capsid protein assembly
2Object-affected harmful factors
If FMDV VLPs are produced in baculovirus expression system, then production safety is improved by avoiding high containment facilities, but productivity is limited by low yield
Solution Approach 1:
The patent employs the baculovirus expression system's natural ability to self-replicate and express recombinant proteins in insect cells. The system automatically produces high levels of capsid proteins through viral infection cycles, eliminating the need for expensive high-containment facilities while achieving productive yields through the virus's inherent replication and protein expression machinery
Solution Approach 2:
The patent optimizes production parameters including infection multiplicity (MOI), incubation time, and cell culture conditions to maximize VLP yield in the baculovirus system. By adjusting these parameters, the system achieves high productivity in low-containment environments, transforming the trade-off into a favorable outcome
3Adaptability or versatility
If FMDV VLPs are produced in baculovirus expression system, then production flexibility is improved by enabling low-containment production, but reliability deteriorates due to low thermostability
Solution Approach 1:
The patent introduces stabilizing amino acid substitutions in the capsid proteins, particularly in the VP1 and VP2 regions. These molecular-level parameter changes enhance thermostability and resistance to environmental stressors, allowing VLPs to maintain structural integrity and immunogenicity under varied storage and transport conditions while retaining production flexibility
Solution Approach 2:
The patent creates a composite structure through proper assembly of multiple capsid proteins (VP1, VP2, VP3, VP4) into quaternary VLP structures. This composite arrangement provides mutual stabilization, where the interactions between different protein subunits enhance overall thermostability and structural resilience, enabling reliable performance in flexible production settings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in more stable and immunogenic FMDV VLPs with higher yields, suitable for vaccine production, addressing the limitations of existing vaccines and improving thermostability and production efficiency.
Implementation Method 1
insect cells capable of recombinantly producing the FMDV VLP
Implementation Method 2
VLPs self-assemble from the processed virus structural proteins, VP0, VP3 and VP1
Implementation Method 3
a substantial part of the VLPs were transported to the cell culture medium, which seems to be an active process
Data Source
AI summary
The invention concerns a method of producing a foot and mouth disease virus (FMDV) virus-like particle (VLP) in a baculovirus expression system, the method comprising the steps of (i) infecting an insect cell with a baculovirus expression vector, (ii) culturing the insect cell in cell culture medium for 5 days or more post infection and (iii) harvesting the FMDV VLP from the cell culture medium. The invention further relates to a vaccine for use in the protection of a subject against an infection with FMDV, the vaccine being obtainable by the method of the invention.